Benzinga · Oct 27, 2026
BTIG Initiates Coverage On DarioHealth with Buy Rating, Announces Price Target of $6
BTIG analyst David Larsen initiates coverage on DarioHealth (NASDAQ:DRIO) with a Buy rating and announces Price Target of $6.
DR
NASDAQ · DRIO
DarioHealth Corp.
Healthcare · Medical - Diagnostics & Research
$3.03
Down-$0.03 (-0.99%)
Updated Nov 3, 2026, 11:37 PM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 86.71M
- P/E ratio
- -51.67
- Dividend yield
- 0.00%
- 52-week range
- $2.95 – $14.77
- Volume
- 76.57K
- Avg. volume
- 68.53K
Price performance · DRIO
DRIO price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
DRIO closed at $3.03 after 21 trading sessions, down 47.76% for the selected period.
- Last close
- $3.03
- Period change
- -47.76%
- Period low
- $3.00
- Period high
- $6.08
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $3.06 | $3.14 | $2.95 | $3.03 | 76.57K |
| Oct 30, 2026 | $3.0344 | $3.32 | $3.00 | $3.00 | 55.53K |
| Oct 29, 2026 | $3.35 | $3.52 | $3.24 | $3.3101 | 59.44K |
| Oct 28, 2026 | $3.56 | $3.76 | $3.22 | $3.41 | 64.98K |
| Oct 27, 2026 | $3.55 | $3.55 | $3.21 | $3.48 | 44.08K |
| Oct 26, 2026 | $3.62 | $4.035 | $3.25 | $3.40 | 99.29K |
| Oct 23, 2026 | $3.43 | $3.77 | $3.27 | $3.77 | 85.44K |
| Oct 22, 2026 | $3.60 | $3.6701 | $3.01 | $3.41 | 198.42K |
| Oct 21, 2026 | $4.10 | $4.20 | $3.125 | $3.68 | 266.18K |
| Oct 20, 2026 | $4.4897 | $4.62 | $3.85 | $4.08 | 132.92K |
| Oct 19, 2026 | $4.82 | $5.3154 | $4.49 | $4.49 | 31.03K |
| Oct 16, 2026 | $5.30 | $5.40 | $4.82 | $4.82 | 26.69K |
| Oct 15, 2026 | $5.45 | $5.45 | $5.025 | $5.13 | 10.33K |
| Oct 14, 2026 | $5.49 | $5.81 | $5.13 | $5.45 | 6.69K |
| Oct 13, 2026 | $5.18 | $5.54 | $5.18 | $5.54 | 9.07K |
| Oct 12, 2026 | $6.36 | $6.365 | $5.325 | $5.42 | 11.3K |
| Oct 9, 2026 | $5.37 | $5.85 | $5.37 | $5.80 | 2.62K |
| Oct 8, 2026 | $6.02 | $6.05 | $5.43 | $5.43 | 38.72K |
| Oct 7, 2026 | $5.93 | $6.29 | $5.93 | $6.08 | 2.61K |
| Oct 6, 2026 | $5.80 | $6.205 | $5.80 | $6.02 | 7.75K |
| Oct 5, 2026 | $6.53 | $6.54 | $5.80 | $5.80 | 26.14K |
Latest DRIO news
The latest Smart Investors Daily articles mentioning DRIO.
Stock researchCompany · Overview
Company
Market Activity
Research & News
DRIO research
Overview
Company profile and research snapshot.
Company profile
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $16.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 27, 2026 | BTIG | Buy | — |
| Aug 19, 2026 | Alliance Global Partners | Buy | — |
| Aug 12, 2026 | TD Cowen | Hold | — |
| Mar 20, 2026 | Stifel | Buy | — |
| May 19, 2025 | Litchfield Hills | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 26, 2026
Dario Expands Contract with a Leading Regional Grocery Retailer, Adding Women's Digital Health and Clinical Care Program
DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced that a leading regional grocery retailer client has expanded its contract with Dario to add Dario Women™, the Company's recently launched women's health solution supporting women navigating perimenopause and menopause symptoms. The expanded program will be offered to eligible insured employees in January
Benzinga · Oct 26, 2026
DarioHealth Expands Contract With Dario To Add Dario Women, Recently Launched Women's Health Solution Supporting Women Navigating Perimenopause And Menopause Symptoms
Contract extension follows benefits realized from Dario's cardiometabolic program and strong employee demand for perimenopause supportNearly 45% of Dario's current book of business is women over age 40 who could
Yahoo · Oct 6, 2026
DarioHealth Announces Independent Aon Analysis that Supports Estimated 2.5%-7.2% In-Year Reduction in Total Healthcare Costs
DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced the results of a review titled "An Independent Review of Evidence Supporting DarioHealth's Clinical and Cost-Savings Impact" conducted by the Managed Care Services Team of Aon plc ("Aon"), a leading global professional services firm.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
